Benign prostate hyperplasia (BPH) is regarded by the most urologists as a progressive condition, which underscores the importance of a proactive approach in patients with older age group with or without combined other medical morbidities. The long term nature of BPH necessitates a therapy that reduces and maintains reduction in enlarged prostate adenoma,
has lasting effects on symptoms and minimizes the risk for adverse outcomes. Hence during the recent decade, we have seen substantial developments in the field of minimally invasive treatment (MIT) for BPH - thermal therapies, laser induced therapies, and chemoablations. Regarding clinical efficacy, conventional transurethral resection of the prostate (TURP)
is still the "treatment of choice". Although changes of subjective symptoms and objective parameters are more profound after TURP than MIT, recovery times and adverse events are improved in MIT compared with TURP. Nowadays, urologists are faced with the challenge of identifying the most appropriate treatment option for the more effective and less invasive
management of BPH. This review focuses on a critical appraisal of contemporary minimally invasive treatment options for BPH.
|